Scarica l'app Stockscreener
36.48
4.89%
1.675
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$34.80
Aprire:
$35.76
Volume 24 ore:
3.47M
Relative Volume:
2.89
Capitalizzazione di mercato:
$3.84B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
28.95
EPS:
1.26
Flusso di cassa netto:
$142.60M
1 W Prestazione:
-55.84%
1M Prestazione:
-54.80%
6M Prestazione:
-48.84%
1 anno Prestazione:
-26.96%
Intervallo 1D:
$35.12
$38.44
Intervallo di 1 settimana:
$32.99
$82.98
Portata 52W:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Confronta CORT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
36.54 | 3.66B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.80 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.54 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.61 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
848.15 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.72 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | UBS | Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
FDA rejects relacorilant for Cushing’s-related high blood pressure - Cushing's Disease News
Corcept Therapeutics (NASDAQ:CORT) Trading Up 9.7%Here's What Happened - MarketBeat
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away - Barchart.com
Implied Volatility Surging for Corcept Stock Options - TradingView — Track All Markets
Canaccord Genuity Adjusts Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Given New $99.00 Price Target at Canaccord Genuity Group - MarketBeat
Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright - Investing.com UK
Corcept Therapeutics stock price target cut by Canaccord on FDA setback - Investing.com Canada
Corcept Therapeutics (CORT) Faces FDA Setback, But Growth Potent - GuruFocus
HC Wainwright & Co. Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - The National Law Review
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT - ts2.tech
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets - ts2.tech
A Risky Spot For Corcept Therapeutics (NASDAQ:CORT) - Seeking Alpha
What drives Corcept Therapeutics Incorporated stock priceTrading Psychology Tips & Build Wealth With Strategy - earlytimes.in
FDA says it needs additional evidence of effectiveness for Corcept relacorilant - Yahoo Finance
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - TradingView — Track All Markets
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56% - simplywall.st
Why We're Not Concerned Yet About Corcept Therapeutics Incorporated's (NASDAQ:CORT) 56% Share Price Plunge - 富途牛牛
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT - ts2.tech
Why Corcept Therapeutics plummeted by 50% today - MSN
Why Corcept Therapeutics Plummeted by 50% Today - The Globe and Mail
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension - ts2.tech
Why Corcept Therapeutics Plummeted by 50% Today - The Motley Fool
Why Corcept (CORT) Shares Are Falling Today - Finviz
Why Corcept Therapeutics stock crashed today and what comes next? - CryptoRank
Corcept stumbles after Cushing's drug met with FDA rebuff - FirstWord Pharma
Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - NewMediaWire
Corcept Therapeutics price target lowered to $50 from $135 at Truist - TipRanks
Corcept Therapeutics Faces FDA Setback for Relacorilant Approval - TipRanks
Corcept Therapeutics Inc Receives FDA Complete Response Letter for Relacorilant - TradingView — Track All Markets
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next - ts2.tech
Stock Traders Buy Large Volume of Put Options on Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Truist Securities Lowers Corcept Therapeutics' Price Target to $50 From $135, Buy Rating Kept - marketscreener.com
Truist Securities lowers Corcept Therapeutics stock price target on FDA concerns - Investing.com Nigeria
US FDA declines to approve Corcept’s drug for rare hormonal disorder - WTAQ
Corcept nosedives 48% after FDA rejected core drug - breakingthenews.net
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply - Benzinga
Nvidia, Tesla, Nike, DJT, Hecla, Newmont, Corcept, Vanda, and More Market Movers - Barron's
Corcept Therapeutics (CORT) Sees Significant Decline in Stock Va - GuruFocus
Corcept Therapeutics Stock (CORT) Opinions on FDA Rejection of Relacorilant - Quiver Quantitative
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug - Barron's
Stocks making the biggest moves midday: Nike, Corcept Therapeutics, Taiwan Semiconductor & more - CNBC
Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing - BioWorld MedTech
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Nvidia, Tesla, Hecla, Newmont, Nike, Vanda, Corcept, DJT, and More Market Movers - Barron's
Wolfe Research Downgrades Corcept Therapeutics to Underperform from Peer Perform, Price Target is $30 - marketscreener.com
Wolfe Research downgrades Corcept Therapeutics stock rating to Underperform By Investing.com - Investing.com UK
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corcept Therapeutics Inc Azioni (CORT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BELANOFF JOSEPH K | Chief Executive Officer |
Dec 24 '25 |
Option Exercise |
3.88 |
550,000 |
2,134,000 |
550,000 |
| Guyer William | Chief Development Officer |
Dec 02 '25 |
Option Exercise |
21.65 |
20,000 |
433,000 |
21,235 |
| Guyer William | Chief Development Officer |
Dec 02 '25 |
Sale |
80.08 |
20,000 |
1,601,526 |
1,235 |
| Maduck Sean | See Remarks |
Dec 01 '25 |
Option Exercise |
8.27 |
20,000 |
165,400 |
27,904 |
| Maduck Sean | See Remarks |
Dec 01 '25 |
Sale |
79.52 |
20,000 |
1,590,490 |
7,904 |
| Lyon Joseph Douglas | See Remarks |
Dec 01 '25 |
Option Exercise |
13.56 |
5,000 |
67,800 |
15,277 |
| Lyon Joseph Douglas | See Remarks |
Dec 01 '25 |
Sale |
79.53 |
5,000 |
397,632 |
10,277 |
| BELANOFF JOSEPH K | Chief Executive Officer |
Dec 01 '25 |
Sale |
79.77 |
40,000 |
3,190,796 |
2,701,370 |
0.52%
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):